GlassScriptPhysician profile
Salah Fares
NPI 1780850974
$5,344.60
in general payments reported to CMS, 2019-2025
31 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $232 · 2021: $5.00 · 2022: $220 · 2023: $768 · 2024: $2,064 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,973 · Education: $1,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,972.78 |
| Education | $1,534.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,534.23 | 2022-2024 | |
| Electromed, INC. | $788.44 | 2022-2025 | Smartvest |
| Glaxosmithkline, LLC. | $703.36 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $406.76 | 2023-2025 | Inspire |
| Insmed, INC. | $233.99 | 2024-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $226.92 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.41 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Pulmonx Corporation | $154.13 | 2020-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Regeneron Healthcare Solutions, INC. | $108.61 | 2019-2025 | Dupixent |
| Philips North America LLC | $107.95 | 2019-2025 | Vest Therapy Und |
| Astrazeneca Pharmaceuticals LP | $102.29 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $81.10 | 2024-2025 | Aralast, Glassia |
| United Therapeutics Corporation | $79.42 | 2021-2025 | Tyvaso |
| Genentech USA, INC. | $76.84 | 2019-2023 | Xolair |
| Novartis Pharmaceuticals Corporation | $53.10 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $52.10 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $49.65 | 2022-2025 | Opsynvi, Uptravi |
| Boston Scientific Corporation | $43.31 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Pfizer INC. | $42.77 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $40.42 | 2025 | Acthar |
| Amgen INC. | $34.00 | 2025 | |
| Gilead Sciences, INC. | $31.99 | 2023-2024 | Veklury |
| Harmony Biosciences LLC | $28.58 | 2023 | Wakix |
| Sunovion Pharmaceuticals INC. | $26.27 | 2019 | |
| Allergan, INC. | $24.42 | 2020 | |
| Abbott Laboratories | $21.32 | 2022 | |
| Optinose US, INC. | $18.36 | 2023 | |
| Amneal Pharmaceuticals LLC | $15.88 | 2025 | Alymsys |
| Shire North American Group INC | $15.73 | 2019 | |
| Merck Sharp & Dohme LLC | $12.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salah Fares listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.